Gardasil is a four-dose vaccine manufactured by Merck & Co. The FDA has approved Gardasil for the prevention of cervical, vulvar and vaginal cancers caused by HPVtypes 16 and 18 infection in women and for the prevention of genital warts caused by HPVtypes 6 and 11. The vaccine is available for women and men aged 9-26 years. The FDA has approved Cervarix for the prevention of cervical cancer caused by HPVtypes 16 and 18 in women aged 10-25 years. Both Gardasil and Cervarix are HPV vaccines based on the research of scientists at the NIH and NCI, and are licensed by the NIH. Both vaccines do not provide complete protection against persistent other types of HPV infection. As a result, about 30% of cervical cancers are not protected by these two vaccines. For Gardasil, about 10% of patients with genital warts are also not protected by the vaccine. In particular, these vaccines do not protect against other sexually transmitted diseases, nor do they treat HPV infection or cervical cancer. Because the vaccine does not completely prevent all HPV infections that can cause cervical cancer, women who have received the HPV vaccine should be screened for cervical cancer on the same regular basis as those who have not been vaccinated.